Award
NIH Reporter #1R43CA310344-01
Enhancing Chemotherapy Efficacy by Targeting the Mutagenic Translesion Synthesis Pathway
Recipient
DAYBREAK PHARMACEUTICALS INC
Award Amount
$303,345.00
Ceiling
$303,345.00
Awarded
July 31, 2026
Identifier
1R43CA310344-01
Award for developing synthetic RNA therapy to improve chemotherapy in non-small cell lung cancer by targeting translesion synthesis pathway.
Description
This project focuses on developing a synthetic RNA-based therapy to inhibit translesion synthesis in non-small cell lung cancer, aiming to improve chemotherapy efficacy and overcome resistance.